HSBC Upgrades AbbVie to Buy, Announces $185 Price Target
Portfolio Pulse from Benzinga Newsdesk
HSBC analyst Rajesh Kumar has upgraded AbbVie (NYSE:ABBV) from Hold to Buy and set a price target of $185.
June 05, 2024 | 10:17 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HSBC analyst Rajesh Kumar has upgraded AbbVie from Hold to Buy and set a price target of $185.
An upgrade from Hold to Buy by a reputable analyst like Rajesh Kumar at HSBC is likely to positively impact AbbVie's stock price in the short term. The new price target of $185 suggests significant upside potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100